Підписатись
Luca Lazzari
Luca Lazzari
IFOM - FIRC Institute of Molecular Oncology
Підтверджена електронна адреса в ifom.eu
Назва
Посилання
Посилання
Рік
Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer
M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ...
Cancer discovery 6 (2), 147-153, 2016
405*2016
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer
M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ...
Cancer discovery 6 (1), 36-44, 2016
295*2016
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
2882014
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
S Arena, B Bellosillo, G Siravegna, A Martínez, I Canadas, L Lazzari, ...
Clinical cancer research 21 (9), 2157-2166, 2015
2802015
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
Journal of the National Cancer Institute 109 (12), 2017
2302017
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ...
Nature communications 7 (1), 13665, 2016
2022016
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver
A Bertocchi, S Carloni, PS Ravenda, G Bertalot, I Spadoni, AL Cascio, ...
Cancer cell 39 (5), 708-724. e11, 2021
1952021
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis
A Gentile, L Lazzari, S Benvenuti, L Trusolino, PM Comoglio
Cancer research 71 (8), 3132-3141, 2011
1662011
Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer
G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ...
Cancer Cell 34 (1), 148-162. e7, 2018
1342018
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
S Lamba, M Russo, C Sun, L Lazzari, C Cancelliere, W Grernrum, ...
Cell reports 8 (5), 1475-1483, 2014
1272014
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
S Arena, G Siravegna, B Mussolin, JD Kearns, BB Wolf, S Misale, ...
Science translational medicine 8 (324), 324ra14-324ra14, 2016
972016
Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction
S Benvenuti, L Lazzari, A Arnesano, G Li Chiavi, A Gentile, PM Comoglio
Cancer research 71 (5), 1945-1955, 2011
832011
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin
S Arena, G Corti, E Durinikova, M Montone, NM Reilly, M Russo, ...
Clinical Cancer Research 26 (6), 1372-1384, 2020
732020
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients
G Crisafulli, A Sartore-Bianchi, L Lazzari, F Pietrantonio, A Amatu, ...
Cancer Discovery 12 (7), 1656-1675, 2022
542022
The ROR1 pseudokinase diversifies signaling outputs in MET‐addicted cancer cells
A Gentile, L Lazzari, S Benvenuti, L Trusolino, PM Comoglio
International journal of cancer 135 (10), 2305-2316, 2014
542014
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer
L Lazzari, G Corti, G Picco, C Isella, M Montone, P Arcella, E Durinikova, ...
Clinical Cancer Research 25 (20), 6243-6259, 2019
512019
Vitamin C restricts the emergence of acquired resistance to EGFR-targeted therapies in colorectal cancer
A Lorenzato, A Magrì, V Matafora, V Audrito, P Arcella, L Lazzari, ...
Cancers 12 (3), 685, 2020
452020
Met-driven invasive growth involves transcriptional regulation of Arhgap12
A Gentile, L D'alessandro, L Lazzari, B Martinoglio, A Bertotti, A Mira, ...
Oncogene 27 (42), 5590-5598, 2008
402008
Amyloid aggregates accumulate in melanoma metastasis modulating YAP activity
V Matafora, F Farris, U Restuccia, S Tamburri, G Martano, C Bernardelli, ...
EMBO reports 21 (9), e50446, 2020
262020
The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.
S Lonardi, C Montagut, F Pietrantonio, E Elez, A Sartore-Bianchi, ...
Journal of Clinical Oncology 38 (15_suppl), TPS4124-TPS4124, 2020
212020
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20